Short Interest in Genenta Science S.p.A. (NASDAQ:GNTA) Declines By 40.0%

Genenta Science S.p.A. (NASDAQ:GNTA) experienced a notable reduction in short interest during February. As of February 28th, the total short interest reached 1,500 shares, marking a 40.0% decline from the 2,500 shares recorded on February 13th. Currently, only a minuscule fraction of the company's stock, about 0.0%, is short sold. Considering the average daily trading volume of 10,400 shares, the ratio of short-interest days is currently at 0.1.

Institutional Investors Take an Interest in Genenta Science

A recent entry into the stock has been made by Citadel Advisors LLC, which purchased a new stake in Genenta Science. This hedge fund acquired 11,167 shares in the fourth quarter, amounting to an investment of around $46,000. As of the latest filing with the Securities and Exchange Commission (SEC), Citadel Advisors LLC holds approximately 0.06% of Genenta Science. In total, institutional investors and hedge funds comprise 15.13% of the company’s stock ownership.

Genenta Science Stock Overview

On a trading day last Friday, GNTA stock witnessed a decline of $0.11, ending the day at $3.84. The trading volume for the day was 1,273 shares, which is below the average of 8,263 shares. The company's 50-day moving average stands at $4.07, while the 200-day moving average is $4.54. Over the past year, Genenta Science's stock reached a low of $2.20 and a high of $7.28.

About Genenta Science

Genenta Science S.p.A. is a biotechnology company in the clinical phase that focuses on developing gene therapies utilizing hematopoietic stem cells to treat solid tumors. Its primary candidate, Temferon, is currently undergoing Phase 1/2a clinical trials for the treatment of glioblastoma multiforme in patients with an unmethylated MGMT gene promoter.

Genenta, Stocks, Investors